Overview

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood. Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.
Phase:
Phase 4
Details
Lead Sponsor:
Therapeutic Concepts
Collaborators:
Abbott
BluKyne
Tibotec, Inc
Treatments:
Etravirine
Lopinavir